Comparative Pharmacology
Head-to-head clinical analysis: DYMISTA versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYMISTA versus OPTOMYCIN.
DYMISTA vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist; fluticasone propionate is a corticosteroid with anti-inflammatory activity. The combination reduces nasal symptoms by blocking histamine receptors and inhibiting inflammatory mediators.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
One spray (137 mcg azelastine hydrochloride/50 mcg fluticasone propionate) per nostril twice daily, intranasal.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Azelastine: terminal half-life ~22 hours (plasma) with long-lasting antihistamine effect. Fluticasone propionate: terminal half-life ~7.8 hours (intravenous), but intranasal systemic exposure is very low.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Azelastine: ~75% renal (primarily as parent and metabolites), ~25% fecal. Fluticasone propionate: <5% renal, >95% fecal as parent and metabolites.
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Antihistamine/Corticosteroid Combination
Ophthalmic Antibiotic/Corticosteroid Combination